Podcasts about Phase

Most service business owners make the same hiring mistake: they either clone themselves or swing too far in the opposite direction. Dave MacDonald, founder of The MacDonald Group, has cracked the code on bringing in leadership that elevates your business without losing what makes it profitable. In this episode, Dave shares his battle-tested approach to hiring leaders who bring proven systems from larger operations—without the disconnect that kills profitability. If you've ever wondered how to scale past $10M, $20M, or beyond without chaos, this conversation is your roadmap. The "Descending Ladder" Hiring Strategy That Changes Everything Dave's counterintuitive approach: hire leaders from companies roughly double your size. Not too small (they won't bring new systems), not too large (they'll lose touch with the hands-on work that drives profit). The sweet spot: If you're running a $20M service business, target leaders from $40M firms. They've seen the systems that work at scale, but they're still close enough to remember the grind. The danger zone: Hiring someone from a $100M operation for your $20M business. They'll design systems for problems you don't have yet—and profitability vanishes while they build their empire. "Throw Them in the Pool" - The Onboarding System That Reveals Everything Forget the standard two-week onboarding playbook. Dave's approach tests what really matters: can they swim when unexpected challenges hit? Phase 1 - The Pool Phase 2 - The Brick Phase 3 - Juggling The Three I's: Building a Culture That Repels the Wrong People Dave's non-negotiable cultural framework filters out mismatches before they become expensive problems: Integrity - Takes a full year to truly assess. You can't shortcut this one. Intensity - Either they match your pace or they don't. Create an environment where low intensity feels awkward. Intentionality - Can be taught, but natural focus is gold. Look for people who think three steps ahead. Systems That Actually Improve (Instead of Just Existing) The Annual Rewrite: Every Standard Operating Procedure gets completely rewritten yearly. Yes, completely. This forces evolution and prevents "we've always done it this way" from killing your growth. The Weekly Rhythm Feedback loops that matter The People-First AI Strategy for Service Businesses Dave's refreshingly practical take on AI: "Old-world values with today's most robust technology." What they're actually using AI for: Writing and presentation creation Back-office automation (invoicing, payroll) Initial candidate screening What they're NOT doing: Chasing bleeding-edge tools that aren't proven Replacing the human connection in recruiting Top-down AI mandates Why This Matters for Your Service Business If you're stuck between $5M and $20M, you're probably missing one thing: leaders who've already solved the problems you're facing. The systems you need exist—you just need someone who's lived them. Dave's approach removes the guesswork. Hire people who've already built what you're trying to build. Test them hard and fast. Build a culture so strong that mediocrity feels uncomfortable. Most importantly: don't let your systems gather dust. Annual rewrites might sound exhausting, but it's the difference between a business that scales and one that plateaus. Want to transform your hiring and onboarding systems? These aren't just recruitment tactics—they're the foundation for scalable growth. The question isn't whether you can afford to implement these systems. It's whether you can afford not to.

In this episode, I talk honestly about the struggles we all face as child-centered play therapists — not as problems to be avoided, but as essential parts of our own therapeutic journey. After two meaningful conversations this week, and in the context of my own recent grief, I've been reflecting on how CCPT doesn't just grow our clients; it grows us. I share how every CCPT clinician eventually hits a wall of resistance, self-doubt, and frustration, and why that moment is actually the turning point toward mastery if we stay the course. I draw parallels between the phases children move through in the playroom and the phases we go through as clinicians — initiation, resistance, work, and ultimately a long, steady season of competence and grounded confidence. This episode is a reminder that resistance is not a sign you're doing something wrong. It's a sign that you're becoming who you're meant to be as a CCPT therapist. When we trust the process for ourselves the same way we trust it for our kids, we emerge stronger, clearer, and more connected to the work than ever. PlayTherapyNow.com is my HUB for everything I do! playtherapynow.com. Sign up for my email newsletter, stay ahead with the latest CCPT CEU courses, personalized coaching opportunities and other opportunities you need to thrive in your CCPT practice. If you click one link in these show notes, this is the one to click! Topical Playlists! All of the podcasts are now grouped into topical playlists on YouTube. Please go to https://www.youtube.com/kidcounselorbrenna/playlists to view them. If you would like to ask me questions directly, check out www.ccptcollective.com, where I host two weekly Zoom calls filled with advanced CCPT case studies and session reviews, as well as member Q&A. You can take advantage of the two-week free trial to see if the CCPT Collective is right for you. Ask Me Questions: Call ‪(813) 812-5525‬, or email: brenna@thekidcounselor.com Brenna's CCPT Hub: https://www.playtherapynow.com CCPT Collective (online community exclusively for CCPTs): https://www.ccptcollective.com Podcast HQ: https://www.playtherapypodcast.com APT Approved Play Therapy CE courses: https://childcenteredtraining.com Facebook: https://facebook.com/playtherapypodcast Common References: Cochran, N., Nordling, W., & Cochran, J. (2010). Child-Centered Play Therapy (1st ed.). Wiley. VanFleet, R., Sywulak, A. E., & Sniscak, C. C. (2010). Child-centered play therapy. Guilford Press. Landreth, G.L. (2023). Play Therapy: The Art of the Relationship (4th ed.). Routledge. Landreth, G.L., & Bratton, S.C. (2019). Child-Parent Relationship Therapy (CPRT): An Evidence-Based 10-Session Filial Therapy Model (2nd ed.). Routledge. https://doi.org/10.4324/9781315537948 Benedict, Helen. Themes in Play Therapy. Used with permission to Heartland Play Therapy Institute.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

Turn online alignment into an offline community — join us at TheWayFwrd.com to connect with like-minded people near you. Have you ever wondered if your phone is quietly rewiring your brain? In this episode, I sit down with Tristan Scott, an electrical engineer turned health researcher who's helping build healthier technology at Daylight Computer. He bridges two worlds that rarely meet: the precision of electrical engineering and the intuition of human biology. And what he's discovered is that our digital tools might be draining more than just our attention. We explore why grounding and sunlight matter more than most people realize, what really happens when EMFs meet the body's own electrical system, and why "energy efficiency" might be costing us our health. Tristan is designing tech that respects human circadian biology instead of hijacking it at Daylight Computer. Because our bodies are already electrical systems, the question is whether we're working with that power or against it. You'll Learn: [00:00] Introduction [00:10:56] The surprising link between Bitcoin, health, and personal sovereignty [00:23:04] Why grounding into your power outlet may be harming you more than helping [00:45:20] The shocking truth about electromagnetic "mind control" experiments [01:03:43] How energy-efficient design quietly removed healing infrared light from our lives [01:09:52] Why working outdoors can literally recharge your biology [01:11:43] The hidden power of cold exposure and mitochondrial uncoupling [01:13:38] Why modern environments are breaking down the body's fourth phase water [01:48:41] When sensitivity returns, your body finally knows what's real [01:55:13] The real reason children lose themselves to screens, and how to fix it Resources Mentioned: Bitcoin and Beef by Tristan Scott | Book or AudiobookThe Way Forward episode on Tuning the Zodiac & Balancing Through Sound featuring Eileen McKusick | Listen NowThe Way Forward episode on The 4th Phase of Water: The Blueprint for Biological Energy with Dr. Gerald Pollack | Listen NowThe Invisible Rainbow by Arthur Firstenberg | Book or AudiobookDanny Hamilton's SunSense | WebsiteCross Currents by Robert Becker | BookThe Body Electric by Robert Becker & Gary Selden | BookThe Anxious Generation by Jonathan Haidt | Book or AudiobookPollock's Paper on Oxygen is an Electron Donor | TelegramThe Brain That Changes Itself by Norman Doidge M.D. | Book or AudiobookJoe Rogan Experience #1235 - Ben Greenfield | Spotify or AppleThe Creature from Jekyll Island by G. Edward Griffin | BookDecentralized Radio Podcast with Tristan Scott and Ryan Brown | Spotify or AppleAires Tech – EMF Protection Devices | WebsiteBio Geometry | Website Visit daylightcomputer.com and use the Code TWF50 for $50 Off. Become a Member of TWF, receive $75 off. Find more from Tristan: Daylight Computer | Website Daylight Computer | InstagramDaylight Computer Kids | WebsiteDaylight Computer Kids | InstagramTristan Scott | XTristan Scott | InstagramTristan Scott | Substack Find more from Alec: Alec Zeck | InstagramAlec Zeck | XThe Way Forward | Instagram   The Way Forward is Sponsored By: RMDY Academy & Collective: Homeopathy Made Accessible High-quality remedies and training to support natural healing.  Enroll here Explore here   New Biology Clinic: Redefine Health from the Ground Up Experience tailored terrain-based health services with consults, livestreams, movement classes, and more. Visit www.NewBiologyClinic.com and use code TheWayForward for $50 off activation. The Way Forward members get the $150 fee waived

This episode includes: #RateMyMeal, teacher makes club gains, oatmeal, nutrition while at theme parks, forearm training and new releases!Join The SwoleFam https://swolenormousx.com/membershipsDownload The Swolenormous App https://swolenormousx.com/swolenormousappMERCH - https://papaswolio.com/Watch the full episodes here: https://rumble.com/thedailyswoleSubmit A Question⁠ For The Show: https://swolenormousx.com/apsGet On Papa Swolio's Email List: https://swolenormousx.com/emailDownload The 7 Pillars Ebook: https://swolenormousx.com/7-Pillars-EbookTry A Swolega Class From Inside Swolenormous X: https://www.swolenormousx.com/swolegaGet Your Free $10 In Bitcoin: https://www.swanbitcoin.com/papaswolio/   Questions? Email Us: Support@Swolenormous.com

Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job.  This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job.  You have online opportunities tomorrow! Participate in the National MS Society's Hispanic LatinX MS Experience Summit, or catch the International Progressive MS Alliance's global webcast, How Existing Drugs Could Transform MS Treatment. We have all the info for you to register for either or both!   If you purchase your health insurance through the ACA Healthcare Marketplace, you've probably already been notified that your premiums will skyrocket in 2026. MS Activist, Sarah Quezada, shares how those premium increases will affect her family. Roche has announced the outcomes of Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS. It's positive news, and we have the details! Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  University of Illinois researchers say yes! We're sharing the details. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: It's National Family Caregiver Month  :22 The MS Care Partner Connection  :34 The National MS Society is hosting the Hispanic LatinX MS Experience Summit TOMORROW!  2:20 The International Progressive MS Alliance Global Webcast is TOMORROW!  2:51 Sarah Quezada shares how astronomical increases in ACA health insurance premiums will affect her family  3:46 Roche announces outcomes for Phase 3 clinical trials for Fenebrutinib and Relapsing MS, and Primary Progressive MS  11:59 Could nanoparticles penetrate the blood-brain barrier and deliver anti-inflammatory medication directly to the central nervous system?  13:43 Diana Grazio discusses how she manages her role as a caregiver while holding down a full-time job  16:07 Share this episode  29:10 Next week's episode  29:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/429 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Online Survey https://s.alchemer.com/s3/Perspectives-on-MS SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy REGISTER: The Hispanic LatinX MS Experience Summit https://nationalmssociety.org/resources/get-support/education-programs-and-library/hispanic-latinx-ms-experience REGISTER: International Progressive MS Alliance Global Webcast https://msif.org/news/2025/11/03/alliance-webcast VISIT: The MS Care Partner Connection https://mscarepartnerconnection.com STUDY: Nanoparticle-Boosted Myeloid-Derived Suppressor Cell Therapy for Immune Reprogramming in Multiple Sclerosis https://www.science.org/doi/10.1126/sciadv.ady4135 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 429 Guests: Sarah Quezada, Diana Grazio Privacy Policy

In this conversation, we discuss the challenges and strategies involved in navigating the first building phase of muscle growth. We explore the psychological side of body image, the importance of mindset, and how nutrition supports long-term progress. We highlight the need for self-acceptance, the importance of managing expectations during physical changes, and the value of community support throughout the journey of personal growth and strength training. Find us on Instagram here: Level Up: https://www.instagram.com/levelup_podcast_/ Sharelle: https://www.instagram.com/sharellegrant/ Dani: https://www.instagram.com/daniantonellos/

The orexin receptor agonists are coming. After years of managing narcolepsy with stimulants, sodium oxybate, and wake-promoting agents, we soon will have medications that target the root cause of the disorder: the loss of orexin signaling. These new drugs—developed by Takeda, Alkermes, and Centessa—aren't just incremental improvements. They represent a genuine shift in how we understand and treat hypersomnolence disorders. In this episode, we will:Define what orexin is and why losing it destabilizes wakefulness, REM boundaries, muscle tone, and cognitionLearn how orexin agonists work—not as stimulants, but as replacement therapy for a missing neurotransmitterFind out why OX2R is the key receptor, and how selective agonists restore stable wakefulness, reduce cataplexy, and normalize attentionReview the available clinical data from the new wave of programs: oveporexton (Takeda), alixorexton (Alkermes), and ORX750 (Centessa)See what makes these drugs different from modafinil, amphetamines, solriamfetol, and oxybate therapiesLearn why Phase 1, Phase 2, and Phase 3 trials matter—with quick insights on how these drugs reached such strong resultsConsider safety and side effects, including what Hy's Law means and why regulators watch liver signals so closelyLook ahead to what these medications may mean for NT1, NT2, IH, and other hypersomnolence disorders in the coming yearsSpeculate why this class represents one of the most exciting moments in modern sleep medicineProduced by: Maeve WinterMore Twitter: @drchriswinter IG: @drchriwinter Threads: @drchriswinter Bluesky: @drchriswinter The Sleep Solution and The Rested Child Thanks for listening and sleep well!

This is the morning All Local update for November 17, 2025.

Recording date: 14th November 2025The precious metals sector is experiencing a convergence of favorable conditions that veteran investors describe as one of the best commodity setups in decades. At the recent Precious Metals Summit in Zurich, industry leaders including Pierre Lassonde, Frank Giustra, and Marc Faber highlighted observable market fundamentals supporting this outlook: global liquidity at record highs, structural demand emerging from technological infrastructure, and mining companies generating unprecedented cash flows while trading at reasonable valuations.Global liquidity continues expanding despite recent volatility. The People's Bank of China maintains liquidity injections, while the New York Fed has announced plans for substantial liquidity injection into US markets during Q1 2026. The recent government shutdown ending will release capital trapped in the treasury system for over a month. This liquidity expansion creates sustained support for precious metals as fiat currency purchasing power deteriorates.A less obvious but transformative demand driver emerges from artificial intelligence infrastructure development. The US needs to build at least 350 gigawatts of power dedicated to AI infrastructure—equivalent to 50 nuclear power plants—representing a trillion-dollar investment cycle for power generation alone. This excludes electrical grids, transmission infrastructure, and computing hardware. Recent government partnerships with Brookfield, Cameco, and Westinghouse for nuclear facility development signal the beginning of infrastructure spending requiring massive copper, steel, and concrete quantities while necessitating continued government liquidity injection supportive of gold prices.Third quarter 2025 results demonstrated the financial leverage inherent in gold mining operations. AngloGold Ashanti increased quarterly operating cash flow from $300 million to $1.4 billion—more than quadrupling while gold prices doubled. Even accounting for the Centamin acquisition contributing 20% of production, cash flow expansion significantly exceeds gold price appreciation. The company now operates with zero net debt, increased dividends, and strategic flexibility for acquisitions or capital returns while trading at roughly half the valuation of Agnico Eagle Mines despite comparable cash generation.K92 Mining offers equally compelling value, posting six consecutive quarters of free cash flow while organically funding construction of a complete new mill, twin declines, and associated infrastructure. The Phase 3 expansion completing commissioning in Q4 2025 will drive significant cash flow growth as throughput increases with minimal incremental operating costs. Operating costs scale favorably—an 800 tonne per day mill requires similar oversight as a 3,000 tonne per day mill. Market valuations have not yet reflected this coming cash flow expansion, creating opportunity for investors who understand the timeline and trust management execution.The M&A cycle is accelerating as producers with pristine balance sheets deploy capital. Recent examples include B2 Gold taking a 19.9% stake in Prospector Generator (now funded with $40 million for 2026 exploration), Probe Gold's acquisition, New Gold's pending takeover, and Gold Fields committing $50 million to junior investments. The competition for quality assets remains in early stages despite this activity.Investment opportunities span the market capitalization spectrum: established producers generating record profits at reasonable valuations, funded developers approaching major cash flow inflections, and well-backed exploration companies positioned for discoveries. Current Q4 volatility represents tactical entry opportunities before typical Q1 seasonal strength, with multiple fundamental drivers supporting sustained outperformance of real assets over the coming decade.Learn more: https://cruxinvestor.comSign up for Crux Investor: https://cruxinvestor.com

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expand their capabilities and portfolios. Similarly, Pfizer's finalized acquisition of Metsera after a fierce bidding war with Novo Nordisk underscores the importance of securing valuable assets to strengthen positioning in critical therapeutic areas, such as obesity treatment, where demand continues to rise.Regulatory milestones remain at the heart of industry progress. Organon and Henlius's Poherdy recently received FDA approval as a biosimilar to Roche's Perjeta, offering a new treatment avenue for HER2-positive breast cancer patients. This approval is noteworthy as biosimilars play an essential role in oncology by providing similar efficacy to original biologics but at reduced costs, thereby enhancing healthcare affordability and accessibility. In Europe, the EMA's Committee for Medicinal Products for Human Use has endorsed several innovative drugs, including Otsuka's Dawnzera for hereditary angioedema and Lilly's Inluriyo for certain cancer types. These endorsements reflect the growing pipeline of treatments addressing both rare genetic disorders and widespread diseases.Merck & Co.'s acquisition of Cidara Therapeutics for $9.2 billion underscores a strategic pivot towards bolstering its antiviral portfolio. This deal is particularly significant given Cidara's promising influenza antiviral candidate, initially abandoned by Johnson & Johnson. In an era where infectious diseases pose ever-evolving challenges, Merck's investment in antivirals reflects a commitment to advancing therapeutic solutions in this crucial area.However, drug development's inherent uncertainties were highlighted by Bristol Myers Squibb and Johnson & Johnson's joint anticoagulant venture, which faced termination due to a Phase 3 trial failure. This setback emphasizes the challenges and risks entailed in developing novel therapeutics, particularly within high-stakes areas like cardiovascular health.Leadership changes can significantly impact corporate strategy, as seen with Bavarian Nordic following an unsuccessful private equity takeover attempt. Such shifts can influence investor confidence and reshape strategic directions.Investment trends also paint an optimistic picture for innovation within the sector. European life sciences investor Medicxi's successful raising of €500 million signifies robust financial support for biotech ventures. This influx of capital is vital for propelling early-stage research and development efforts across Europe, fostering breakthroughs in chronic and rare disease treatments.In terms of scientific innovation, advancements in bispecific antibody production through AI/ML-driven molecular design promise higher yields and enhanced quality. These technological innovations could revolutionize complex biologics manufacturing, potentially accelerating timelines and expanding therapeutic possibilities.The regulatory landscape is seeing significant activity as well. Notably, FDA officials introduced a novel pathway aimed at accelerating gene editing therapies' development and approval. By facilitating faster market entry for personalized medicines, this regulatory innovation could pave the way for treatments tailored to individual genetic profiles.Kyowa Kirin's collaboration with Kura Oncology reached a milestone with FDA approval for an oral medication targeting acute myeloidSupport the show

Right now, TSMC Arizona's completed Fab 21 Phase 1 consumes about 18,000 cubic meters of water every day. That's about 4.75 million gallons of water, each day. And there are two more phases coming up. Semiconductor manufacturing is water intensive and that has made some people anxious about TSMC's arrival to the Arizona desert. More than a few people have asked, "Don't these fabs use a ton of water? Why are we building them in the desert?" The answer of course is that Phoenix offers TSMC certain things that are not easily found elsewhere. Water is scarce there, sure. But it is not impossible to find, the amounts are manageable, and it can be recycled. Some claim the facility is stealing water from farmers. Saying, “You can't eat chips!” (Technically you can) The implication being we can only have one or the other. I don't think that's true. Farms use way more water than TSMC. In today's video, I want to revisit the fab in the desert and take a dip into the water situation.

Right now, TSMC Arizona's completed Fab 21 Phase 1 consumes about 18,000 cubic meters of water every day. That's about 4.75 million gallons of water, each day. And there are two more phases coming up. Semiconductor manufacturing is water intensive and that has made some people anxious about TSMC's arrival to the Arizona desert. More than a few people have asked, "Don't these fabs use a ton of water? Why are we building them in the desert?" The answer of course is that Phoenix offers TSMC certain things that are not easily found elsewhere. Water is scarce there, sure. But it is not impossible to find, the amounts are manageable, and it can be recycled. Some claim the facility is stealing water from farmers. Saying, “You can't eat chips!” (Technically you can) The implication being we can only have one or the other. I don't think that's true. Farms use way more water than TSMC. In today's video, I want to revisit the fab in the desert and take a dip into the water situation.

Sind steigende Löhne wirklich ein Gewinn für alle? Die Befürworter des Mindestlohns und seiner weiteren Steigerung verweisen auf den bisherigen Erfolg des Instruments. Und in der Tat hatte der deutliche Anstieg des Mindestlohnes seit seiner Einführung 2015 von 8,50 Euro je Stunde auf heute 12,82 Euro keinen messbaren negativen Effekt auf die Beschäftigung. Trotz einer durchschnittlichen Lohnsteigerung von 5 Prozent pro Jahr, die nach Inflation zu real rund 15 Prozent höheren Mindestlöhnen geführt hat. In den kommenden zwei Jahren soll der Mindestlohn um weitere 14 Prozent bis auf 14,60 Euro (2027) steigen. Die Optimisten erwarten auch künftig keine negative Beschäftigungswirkung, schließlich sei es doch nur gerechtfertigt, dass man von seinem Einkommen leben können muss. Wer könnte da schon widersprechen? Nur ist die Zeit der progressiven Entwicklung des Mindestlohns eine besonders gute Phase in der deutschen Wirtschaftsgeschichte gewesen. Daraus zu schließen, man könne einfach so weitermachen wie bisher, könnte sich als naiv erweisen.Besonders spannend: Daniel Stelters Gespräch mit Dr. Effrosyni (Efi) Adamopoulou, stellvertretende Leiterin des Forschungsbereichs „Ungleichheit und Verteilungspolitik“ am ZEW Mannheim. Sie erklärt, wie Mindestlöhne innerhalb von Unternehmen wirken, warum sie Produktivitätsschocks ungleich verteilen und weshalb Kurzarbeit eine bessere Antwort auf Krisen sein kann als Entlassungen. Eine Episode über die feine Balance zwischen sozialer Gerechtigkeit, Wettbewerbsfähigkeit und ökonomischer Vernunft.HörerserviceStudie Minimum Wages, Productivity, and Reallocation des IZA - Institute of Labor Economics finden Sie hier: https://is.gd/bnkMpCEconomist-Artikel What harm do minimum wages do? - Three decades of research have led to a rethink: https://is.gd/xM8vADStudie Minimum Wages and Insurance within the Firm des ZEW zum Mindestlohn: https://is.gd/pFndEo beyond the obviousNeue Analysen, Kommentare und Einschätzungen zur Wirtschafts- und Finanzlage finden Sie unter think-bto.com.NewsletterDen monatlichen bto-Newsletter abonnieren Sie hier.RedaktionskontaktWir freuen uns über Ihre Meinungen, Anregungen und Kritik unter podcast@think-bto.com.ShownotesHandelsblatt-Aktion vom 14. November bis 8. Dezember 2025 – Für alle, die schon länger mit einem Handelsblatt-Abo liebäugeln: Das gibt es jetzt für 12 Monate mit 50 % Rabatt – gedruckt oder digital. Mit fundierten Recherchen, starken Meinungen und exklusiven Hintergründen behalten Sie den Überblick über die wichtigsten Wirtschaftsthemen. Das Aktionsangebot finden Sie unter handelsblatt.com/podcast50. WerbepartnerInformationen zu den Angeboten unserer aktuellen Werbepartner finden Sie hier. Hosted on Acast. See acast.com/privacy for more information.

In dieser Folge reflektiere ich über meinen Weg zu diesem Podcast, insbesondere in Zusammenhang mit der Corona-Pandemie, welche mir damals die Chance gegeben hat, mich kreativ zu entfalten, neue Leidenschaften zu entdecken und große Projekte anzugehen. Ich erzähle, wie diese Phase meinen Einstieg in die Medienwelt geprägt hat und wieso jeder einzelne Schritt, der daraufhin folgte, unerlässlich war - unerlässlich für meinen Lebensweg und diesen Podcast, der mich stets begleitet hat. Ein großer Teil dessen, was „Banu and You“ ausmacht, steckt schon im Namen selbst. Es geht hier nicht nur um mich - sondern um uns. Deshalb bedanke ich mich von Herzen für jeden einzelnen, der sich sonntags um 18:00 Uhr auf diesen Austausch einlässt. Viel Spaß beim Anhören!Hier kannst du mich abonnieren & exklusive Inhalte anhören: https://podcasters.spotify.com/pod/show/banusjournal/subscribeMein WhatsApp-Kanal: https://whatsapp.com/channel/0029VacCNG9DeONFf8H8n70yMein Pinterest: https://pin.it/2jPEKUrUqMein Spotify: https://open.spotify.com/user/0wsxz9qpvr7z4iakfdcqngj4a?si=46f9e599851d4085Die Folge übers Podcasting: https://open.spotify.com/episode/758E6IjNxN6R0ZCA1VIUoM?si=8d5c0731e5224897Die Folgen über meine Zeit auf Social Media: https://open.spotify.com/episode/2Nmna3YnjW5Gf4h41g6ery?si=937cfc9c3ace439ehttps://open.spotify.com/episode/5uhKw0LwQAeodia68BWptL?si=c2bb03524bcb4083 

LSD shows promise for anxiety treatment. A Phase 2b clinical trial found that 100 micrograms of MM120 (pharmaceutical LSD) reduced anxiety significantly with lasting effects Study results were encouraging. Researchers noted that 65% of participants experienced clinical response at optimal dosing, with 47.5% achieving remission that sustained through 12 weeks of follow-up Safety profile was manageable. Most side effects occurred during dosing sessions and resolved quickly, with visual changes and nausea being most common under medical supervision Note that LSD remains illegal. It is currently classified as Schedule I controlled substance, accessible only through approved clinical trials, with results of Phase 3 trials expected by 2026 In the meantime, natural anxiety alternatives exist. Breathing techniques like nasal breathing, horizontal breathing patterns, and controlled breathing practices can help manage anxiety symptoms without medication

durée : 00:19:08 - L'invité de 8h20 - Benjamin Stora, historien, professeur émérite des universités, président de la partie française de la commission mixte des historiens algériens et français, dernier ouvrage avec Thomas Snegaroff “France, Algérie. Anatomie d'une déchirure” (Les Arènes) est l'invité de 8h20. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

For the second time in 4 weeks, Jim "Smitty" Smith joins Joe for an "off the cuff" podcast conversation! Specific topics discussed include: Behind-the-scenes insight into Phase 2 of Built Different; A nuanced approach to training variability (and programming in 4-week blocks); 3 things that the "happiest people in the world" always have; Valuable gym lessons from high achievers; How to get your weaker limb stronger in record time; Remembering Mike Mentzer; The difference between "science-based coaches" & "science-based KIDS"; How to blow up your biceps in ONE iNsAnE set...And so much more! *For a full list of Show Notes + Timestamps visit www.IndustrialStrengthShow.com. IMPORTANT LINKS Team Forever Strong [FREE Trial] Iron Business Blueprint [Apply Now] Smitty's Instagram Joe D's Instagram Manukora Honey

Carl Rivera is the Chief Design Officer at Shopify, where he previously led both Merchant Services and the Shop App as VP of Product. Before joining Shopify through its acquisition of Tictail, Carl was the co-founder and CEO of Tictail, the "Tumblr for e-commerce," where he built one of the most beloved design-forward commerce platforms of its era. AGENDA: 05:05 Biggest Lessons from Selling My Company to Shopify 09:55 Where Does Shopify Suck at Product: Lessons from that? 17:37 What makes Truly Great product Design: The Five Pillars 31:02 The Future of Design in an AI-Driven World 36:00 Do We Skip the Design Phase in AI: Figma's Evolving Role in Design 40:09 Remote Work vs. In-Person Collaboration: Where Remote Loses? 42:43 What Happens to the Vibe Coding Market 47:06 Product Management and Team Dynamics 59:48 Does AI Favour Incumbents or Startups  

Send us a text if you want to be on the Podcast & explain why!Most new trainers don't fail because they're lazy—they fail because they were set up to memorize, not to coach. We sit down with Cori, a dedicated runner navigating NASM overwhelm, and turn tangled chapters into clear, usable coaching. You'll hear how to translate planes of motion into exercises you can demo immediately, how to spot agonists and antagonists without guessing, and how to use synergists and stabilizers to make your cues land.We walk through the OPT model the way hiring managers want to hear it: Phase 1 builds control and competency, Phase 2 pairs stable with less stable for smarter supersets, Phase 3 drives muscle, Phase 4 loads heavy for strength, and Phase 5 blends power and strength with purpose. You'll get a no-fluff take on energy systems and fiber types—anchored to duration and intensity—so exam questions become quick wins. Then we make assessments useful: identify what “arms fall” and “knees cave” really mean, apply the red-versus-green muscle lists, and choose fixes that actually change movement. Foam roll and stretch what's tight, strengthen what's sleepy, and cue breathing and bracing so reps look and feel better.Safety and screening matter, so we hit the essentials: PAR-Q, hypertension basics, the SA node, and knowing when to refer out. More importantly, we show how hands-on learning, live feedback, and mentorship build confidence faster than any textbook—because clients won't ask about amortization, they'll ask for results. If you've been grinding through chapters and still feel stuck, this conversation gives you a study map, coaching language, and a training method you can use tomorrow.If this helped you see the path more clearly, follow the show, share it with a trainer friend, and leave a quick review—it helps more future coaches find their footing.Want to ask us a question? Email email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show! Our Instagram: Show Up Fitness CPT TikTok: Show Up Fitness CPT Website: https://www.showupfitness.com/Become a Personal Trainer Book (Amazon): https://www.amazon.com/How-Become-Personal-Trainer-Successful/dp/B08WS992F8NASM / ACE / ISSA study guide: https://www.showupfitness.com/collections/nasm

"All you folks that want $5,000 gold and $10,000 gold — be careful what you wish for. That's not the kind of world you want to live in." — Frank GiustraIn today's interview with Daniela Cambone at the Precious Metals Summit in Zurich, Giustra delivers a masterclass on the seismic shifts reshaping global finance, the explosive run in gold, and the looming battle for monetary supremacy.He argues that the weaponization of the U.S. dollar has fueled an unstoppable de-dollarization trend, paving the way for a China-led “digital superhighway” that could challenge the dollar's global standing. Giustra breaks down why efforts to “dollarize” other economies are a non-starter — and why the real threat to U.S. dominance may be the gold-backed system already taking shape across the Global South.✅ FREE RESOURCESDownload The Private Wealth Playbook — a data-backed guide to strategically acquiring gold and silver for maximum protection, privacy, and performance. Plus, get Daniela Cambone's Top 10 Lessons to safeguard your wealth (FREE)

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, "NEALS 2025: Takeaways That Matter for ALS Care," ALS experts Jinsy Andrews, MD, MSc, and James Berry, MD, MPH, reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for ALS. They discuss format changes that elevated lightning science, the expanding gene therapy pipeline, and a growing slate of NEALS-affiliated trials. The conversation highlights updates from the HEALEY Platform Trial, the MY-MATCH biomarker-guided precision trial, SOD1 program data, and new antisense and viral vector therapies aimed at sporadic ALS. They also explore the impact of Act for ALS on trial access, the ALL ALS biospecimen repository, and NIH-supported expanded access cohorts. The discussion closes with insights on combination therapy strategies, genetic subtypes, presymptomatic enrollment, and how new collaborations, digital endpoints, and infrastructure advances are shaping momentum heading into 2026. Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page. Episode Breakdown: 1:05 – Reflections on meeting highlights and NEALS rebranding into a global network 5:00 – Notable NEALS-affiliated trials and promising new mechanisms in ALS care 12:45 – Combination therapy strategies and future approaches in ALS research 15:20 – Neurology News Minute 18:00 – Expanding clinical trial access for rare and genetic ALS subtypes 22:10 – Building momentum and expectations for the 2026 NEALS Annual Meeting The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency Supplemental New Drug Application Submitted for AXS-05 as Treatment for Alzheimer Disease Agitation BTK Inhibitor Fenebrutinib Meets Primary End Points in Phase 3 Trials for Both Relapsing and Primary Progressive MS  Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

We had a few technical issues with last week's broadcast so we've cut to the chase and brought you a mini episode featuring the launch of Phase 3 of our Safeguarding work. You can donate to the podcast via our Paypal link @21stCenturySaints or via https://donorbox.org/21st-century-saints-fundraiserDon't forget to subscribe to our channel here on YouTube. You can also like our Facebook page https://www.facebook.com/21stcenturysaints

For the second time in 4 weeks, Jim "Smitty" Smith joins Joe for an "off the cuff" podcast conversation! Specific topics discussed include: Behind-the-scenes insight into Phase 2 of Built Different; A nuanced approach to training variability (and programming in 4-week blocks); 3 things that the "happiest people in the world" always have; Valuable gym lessons from high achievers; How to get your weaker limb stronger in record time; Remembering Mike Mentzer; The difference between "science-based coaches" & "science-based KIDS"; How to blow up your biceps in ONE iNsAnE set...And so much more! *For a full list of Show Notes + Timestamps visit www.IndustrialStrengthShow.com. IMPORTANT LINKS Team Forever Strong [FREE Trial] Iron Business Blueprint [Apply Now] Smitty's Instagram Joe D's Instagram Manukora Honey

14 Nov 2025. Dubai Chambers is heading to the US, opening its first American office in New York, an announcement made at the Dubai Business Forum. Executive reporter Georgia Tolley speaks to H.E. Eng. Sultan Bin Saeed Al Mansoori about what this means for global trade ties. Plus, with the Dubai Airshow just days away, we check in with DXB Airport CEO Paul Griffiths on what to expect. And Parsons has secured a 56-million-dollar contract for Phase 2 of the Diriyah development, we hear what’s next for one of Saudi Arabia’s biggest giga-projects.See omnystudio.com/listener for privacy information.

Hello Beloved. In a world where our attention spans are shrinking, true hope for our livelihoods—and our lives—emerges when we step beyond binary thinking. Embracing shades of gray opens the door to richer, more nuanced perspectives on every situation.By accepting that multiple truths can coexist, we lift the crushing weight of forcing every decision into a rigid right-or-wrong box.Nurturing trust in our intuition and inner wisdom erodes the compulsion for constant external approval or lengthy defenses.This quiet inner confidence fortifies the seamless harmony of body, mind, heart, and soul, while awakening our natural capacity to weather doubt and exhaustion.What Holds Us Back from Revelations of Self-CompassionThe Moment Everything Changes — exists at a threshold in a moment when the familiar path and the unknown future collide. Here, we stand at the Choice Point.It's not a single decision. It's a recurring crossroads where we face the most primal question: Asking: Do I stay with what I know, or do I step toward what calls me?The First SOVEREIGN SOUNDS SERIES Podcast showcases the etymological breakdown (more fun than you think - super empowering) through the story of Florence Nightingale back in 1854, choosing to leave her comfortable English life to revolutionize medicine in a war-torn hospital that told through the ETYMOLOGY of “COMPASSION".”If you want to hear and transform your relation to this word, you can upgrade at any point to unlock The Light Between Oracle App + Private Episodes where I channel these downloads. Dismantling the Four Walls of Self-DoubtYou face it every time you consider leaving a job, ending a relationship, speaking a truth, or claiming your authentic self.The Choice Point is where transformation begins. But it's also where most of us freeze.Understanding the forces that keep us paralyzed at the threshold—and more importantly, how to move through them—is the work of reclaiming our power.The Four Walls of the PrisonFear of the Unknown: The Primary ObstacleFear is the gatekeeper of the Choice Point.Not the fear of failure or consequences—though those exist. The deepest, most paralyzing fear is the fear of not knowing what comes next. Our nervous systems are wired for certainty. Uncertainty triggers our threat-detection systems.When we contemplate the unknown, our amygdala fires. Our breath shortens. We retreat to what we know, even if it's painful, because painful and known feels safer than uncertain and new.This is why people stay in unfulfilling jobs, relationships that drain them, and lives that don't fit. The devil you know is more manageable than the devil you don't.The truth: The unknown is not dangerous—it's just unfamiliar. And familiarity is not safety; it's often just habit wearing the mask of security.Attachment to Past Patterns and “Known Suffering”There's a paradox at the heart of human psychology: We become attached to our pain.Our wounds become our identity. Our limiting beliefs become our armor. The story we've told ourselves for years—“I'm not worthy,” “I'm too broken,” “People like me don't get to have that”—becomes so familiar that it feels like truth.When offered the possibility of transformation, we unconsciously cling to the pattern. Because at least we know how to survive it. At least there's a narrative. At least there's a reason.This is what psychologists call the “comfort in suffering”—the twisted familiarity that makes even pain feel like home.The Choice Point asks us to grieve what we're leaving behind, even if it was killing us. And that grief is real. That loss is real. Even when the old pattern was destructive, letting it go means losing an identity we've spent years constructing.The truth: Healing requires grieving. But the cost of staying is always higher than the cost of going.Narrow Paths vs. Opening to Infinite PossibilitiesHere's something CRITICAL and why active concious thinking is foundational. Our minds are pattern-recognition machines designed for efficiency, not expansion.The mind works by creating neural pathways. The more we travel a particular thought or behavior, the deeper the groove becomes. Over time, these grooves feel like the only paths available. The mind literally cannot perceive possibilities outside these worn tracks.This is called “cognitive narrowing,” and it's hardwired into our neurology.When faced with a Choice Point, the mind does what it's trained to do: it generates only the solutions it's already mapped. It says, Here are your three options” when actually there are 300. It insists, “This is realistic” while dismissing what's possible as fantasy.We are collectively re-aligning the “all is mind.”The Choice Point isn't just about willpower or courage. It's about expanding the mental field itself—opening to possibilities the conditioned mind cannot yet perceive.This requires what we might call a “frequency shift”—a change in consciousness that literally opens new neural pathways and allows previously invisible solutions to appear.Trust: The Key That Unlocks the TransitionAll three obstacles—fear, attachment, and mental narrowing—lock together into one immovable wall: lack of trust.Trust in ourselves. Trust in the process. Trust that the ground will hold us when we take a step into the unknown.Without trust, we're trying to move through the Choice Point while our nervous system screams “danger.” We're negotiating with fear rather than transcending it.But trust isn't blind faith. It's not ignoring real risks or pretending danger doesn't exist.True trust is remembering that you've already survived every difficult moment in your life. You've moved through uncertainty before. Your body knows how to adapt. Your spirit has weathered storms you thought would destroy you.Trust is recognizing that there's an intelligence working through you—not just your rational mind, but your intuition, your embodied wisdom, your spiritual knowing. Align with that larger intelligence and each Choice Point becomes navigable.This is where language transforms the nervous system itself. When we reclaim the word Trust from its distorted meanings—blind obedience, naïveté, passivity—and return it to its root (a Germanic word meaning “to comfort” or “to strengthen”), we literally change our nervous system's response to the unknown.The truth: You have everything you need to move through the Choice Point. You just need to remember it.The Evolution of Language: How We Lost Our WayFrom Collective Intuition to Fragmented Mind - our ancestors didn't face the Choice Point as we do.Early human societies operated from a place of collective intuition—a kind of group consciousness where decisions emerged from shared sensing rather than individual analysis. Bodies, hearts, and minds moved as one intelligence.There was no paralyzing individual choice. There was knowing. A seamless trust in the collective direction.Then came language.Language was revolutionary and traumatic simultaneously.Words gave us the ability to communicate across time and space. They allowed civilization to build. But they also fragmented us. Words separated the knower from the known. They created subject and object, self and other, safety and danger.As language developed, it slowly replaced embodied knowing with mental analysis. We stopped trusting our gut. We started overthinking. We moved from intuition to ideology.By the time we reached the Enlightenment, trust in the mind had become supreme—and trust in the body, intuition, and collective wisdom had atrophied almost completely.This is why the Choice Point feels so isolating and terrifying now. We're making the decision alone, with only the overthinking mind as our guide. We've lost access to the embodied wisdom and collective knowing that would make the transition feel natural.The Body, the Heart, and Language All Different Channels of KnowingHere's a crucial distinction: The body and mind speak different languages.The body knows through sensation and intuition. It receives information instantaneously—what some call “gut feeling” or “heart knowing.” This wisdom doesn't require analysis. It just is.The mind knows through logic, language, and analysis. It requires evidence, reasoning, and time to process.Neither is superior. They're complementary intelligence systems.But as language became the dominant channel of communication, the body's wisdom became marginalized. We learned to doubt our gut. We were told to “think logically” and ignore our feelings. We were trained to second-guess intuition and defer to external expertise.This created a crisis at the Choice Point: We're using only half our intelligence to make full-life decisions.The path through the Choice Point requires both channels:The mind to discern the practical details and logistics The body to feel the rightness or wrongness of the direction The heart to connect with why this choice matters The spirit to sense the alignment with our larger soul purposeWhen all four are integrated, the Choice Point becomes a place of clarity rather than paralysis.Language as a Living Entity: How Words Shape Our ChoicesHere's where things get deeply revolutionary: Language is not fixed. It breathes.Words are living frequencies that carry the imprint of human consciousness across time. When a culture shifts, words shift with it. And when we understand how a word has been distorted, we can reclaim its original power.Consider how certain words—like Trust, Faith, Surrender, Intuition—have been shaped and twisted by different historical periods.Medieval Europe: Trust was tied to God and divine order. There was a collective framework holding the trust.Industrial Revolution: Trust narrowed. It became about institutions and external authority. Trust in the system. Trust in the expert. Trust in the hierarchy.Modern Era: Trust fragmented further. We distrust institutions. We distrust expertise. We distrust each other. And most dangerously, we distrust ourselves.The result: We're trying to move through the Choice Point with no trust at all.And, my beloved…. here's the liberation: By understanding how the word has been distorted, we can restore its original frequency.When we trace Trust back to its roots—to mean “to comfort,” “to strengthen,” “to hold steady”—we access a different nervous system response. We're not just intellectually deciding to trust. We're activating a frequency in our body that remembers trust as a felt experience, not a concept. Words are spells and shape consciousness.The Architecture of the Choice Point: Three PhasesTransformation at the Choice Point unfolds in distinct phases:Phase 1: Awareness (The Recognition)You begin to see that the current path no longer fits. Something is calling. The discomfort that once seemed normal now feels intolerable.This is where most people get stuck—they see the problem but convince themselves to adjust to it rather than change it. They re-narrate the suffering as meaningful. They spiritualize their dysfunction.True awareness requires honest grief: admitting that something in your life is not working.Phase 2: The Threshold (The Fear)You stand at the actual Choice Point. The old path is visible behind you. The new path is invisible ahead of you.This is where all four obstacles crystallize: Fear screams Attachment pulls backward The mind insists the new path doesn't exist Trust evaporatesThis phase is not meant to be comfortable. Discomfort at the Choice Point is a sign of integrity, not a sign to turn back.Phase 3: The Leap and Landing (The Integration)You move through. The ground holds. You begin to integrate the new frequency. The new path becomes visible as you walk it—not before.Most people want to see the entire new path before they step forward. But that's not how transformation works. We get vision as we move, not before.Four Practices for Moving Through the Choice Point* Embody Your BodyPractice feeling sensation without narrative. Place your hand on your heart. Notice: What does your body know that your mind hasn't admitted yet?Your body doesn't lie. It carries wisdom your mind has trained itself to ignore.Reclaim Trust as a FrequencyRepeat: “I remember the word. I reclaim the root. I restore the power.”Place your hand on your heart and feel what trust actually feels like—not as a concept, but as a sensation of being held, strengthened, comforted.* Expand Your Mental FieldAsk: “What possibilities exist beyond what I can currently imagine?”This simple question opens neural pathways. It signals your brain that there are more options than the three the conditioned mind has offered.Connect to Collective KnowingYou don't have to figure this out alone. There's an intelligence working through human history, through your bloodline, through the zeitgeist of this moment.Ask: “What wants to emerge through me? What is my soul's larger purpose in this transition?”Express Your Choice Point ExerciseIn Closing: While the new paradigm hasn't fully materialized yet. We're all standing in the threshold together.The opportunity is that we're not paralyzed alone anymore. We're standing at the threshold with millions of others who are also choosing to evolve. The Mantra for the Choice PointAs you contemplate your own threshold, return to this again and again:I remember: My body knows. My intuition knows. My spirit knows. I've survived every difficult moment. I have access to more wisdom than my overthinking mind.Surrender as power, not weakness.Intuition as light intelligence, not fantasy.I restore: The power to choose. The power to transform. The power to walk into the unknown and have it become known as I move. CHOOSE to Deepen Your ExplorationThis deep exploration is a small reflection of The Sovereign Sounds Series Podcast that creates one word as a conceptual map of a Choice Point. The vertical energetic origin and the horizontal effects through time as it became a frequency of power over and power under. The Choice Point is calling. Trust is the key. And you have everything you need to move through.Incantations and Reflections for IntegrationAs you sit with this exploration, journal on:* Where am I standing at a Choice Point right now—even if I haven't fully admitted it?* What pattern am I most attached to, even though it no longer serves me?PS: Be on the lookout for the first privast podcast drop and over $258+ intuitive enriching resources to help you on your evolutionary journey. Join and upgrade HERE!Kassandra Get full access to The Light Between at thelightbetween.substack.com/subscribe

We had a few technical issues with last week's broadcast so we've cut to the chase and brought you a mini episode featuring the launch of Phase 3 of our Safeguarding work. You can donate to the podcast via our Paypal link @21stCenturySaints or via https://donorbox.org/21st-century-saints-fundraiserDon't forget to subscribe to our channel here on YouTube. You can also like our Facebook page https://www.facebook.com/21stcenturysaints

Buy/Stream: https://overview.fanlink.tv/OVR118-Phase Widely acclaimed Belgian producer Phase steps forward for his Overview Music debut, the incredible ‘Blinded EP'. No stranger to heavy club orientated Drum & Bass, Phase embarks further into this territory, experimenting with new mid range led synth work, resulting in some of his most aggressive yet distinct music yet. Out 14.11 Phase Instagram → https://www.instagram.com/phasednb Facebook → https://www.facebook.com/phasednb Soundcloud → https://soundcloud.com/phasednb Overview Music Patreon → https://patreon.com/overview Facebook → https://facebook.com/overviewuk Instagram → https://instagram.com/overviewuk Soundcloud → https://soundcloud.com/overviewuk YouTube → https://youtube.com/@OverviewMusic

On this week's episode, John Maraganore, Yaron Werber, Ami Fadia, and special guests STAT's Allison DeAngelis and Endpoints News' Drew Armstrong kick things off with an overview of the latest FDA staffing changes, including long-time oncology chief Richard Pazdur's appointment as the new CDER director, a move the co-hosts view as positive for the industry and a sign of potential stability. Next, the group breaks down the FDA's new ‘Plausible Mechanism Pathway', designed to accelerate certain personalized therapies to market when traditional trials aren't feasible. Allison then shares insights from her reporting on the exclusive MAHA Summit held earlier this week -- an invite-only gathering of top HHS officials and leading biotech executives. In data news, the co-hosts discuss Alkermes' Phase 2 narcolepsy trial, Cogent's Phase 3 gastrointestinal stromal tumor results, and CRISPR's cholesterol data. As one bidding war ends, another begins as Alkermes' move to acquire Avadel faces competition from Lundbeck, who offered a $2.25 billion, rivaling Alkermes' initial $2.1 billion offer. Drew Armstrong also overviewed his reporting on the Novo Nordisk-Pfizer bidding war, noting both companies' obesity setbacks and their search for new directions. Deal-making conversations continues with Merck's $9.2 billion acquisition of Cidara Therapeutics, and Day One Therapeutics' $285 million acquisition of Mersana Therapeutics. The episode concludes with a discussion on the passing of genetic pioneer James Watson and Eli Lilly CEO David Ricks' appearance on The Cheeky Pint podcast. *This episode aired on November 14, 2025.

Mike Maloney: Gold, Silver Bull Run in Final Phase, I Expect "Spectacular" Prices Mike Maloney of ‪@Goldsilver explains why this time really is different for gold and silver, pointing to factors including growing mainstream adoption, and noting that much more of the world's population is able to buy precious metals than in previous cycles. "This is just like a whole new world — this to me signals the beginning of the third and final phase of the bull market — and that is where you have the greatest amount of gains in the shortest period of time. So we should be seeing some fireworks coming," he said.   Watch this video at- https://youtu.be/Yl7B9tFCicY?si=JktrazBIo4z-WbCT Investing News 59.9K subscribers 14,720 views Nov 11, 2025 #Investing #Gold #Silver ❓ Is the gold-silver ratio part of your buying strategy? Tell us in the comments! Read free chapters of Mike's book: https://ggsr21.com/ This interview was filmed on November 3, 2025. #Investing #Gold #Silver 0:00 - Intro 1:20 - This time is really different 4:47 - Final phase of bull market 7:49 - "Giant crisis" in the works 11:21 - Trigger for market crash 13:15 - Farmland offers protection 15:25 - Gold-silver ratio strategy 19:47 - Gold, silver price potential 23:11 - Outro ________________________________________________________________ Investing News Network (INN) Find out more about investing by INN @ https://investingnews.com/ Browse our 2025 outlook reports: http://bit.ly/3JHyR1M Follow us on Facebook:   / investing.news.your.trusted.source   Follow us on Twitter: https://x.com/inn_resource

In this episode, ARK's Cathie Wood and Brett Winton sit down with Sean McClain, Founder and CEO of AbSci, to explore how generative AI is reshaping drug discovery, development timelines, and clinical costs. Sean walks through real-world examples of AI-designed antibodies—such as AbSci's breakthrough HIV antibody and a regenerative treatment for hair loss—and explains how these platforms are helping unlock previously “undruggable” biology.They discuss AbSci's Phase 2-ready hair growth antibody (BS201), the company's partnerships with Caltech and AMD, and why the FDA's evolving embrace of AI could accelerate the end of animal testing. The conversation closes with a forward-looking discussion on the role of regenerative medicine in longevity—and why AI drug discovery might just pull biotech out of its multi-year bear market.Key Points From This Episode:(00:00:00) How AbSci uses generative AI to design antibodies from scratch(00:02:42) HIV, ion channels, and the promise of targeting "undruggable" biology(00:06:28) AbSci's BS201 drug for hair regrowth: mechanism, speed, and cost advantages(00:13:20) Clinical timeline: From concept to Phase 2 readout in 3.5 years(00:15:34) Bringing costs down: $100–150M vs. the industry average of $2.4B(00:17:36) Why AI enables “keys designed for specific locks” in drug targeting(00:22:58) What AbSci's models are trained on—and how prompts work in drug inference(00:25:32) The future of clinical testing: AI replacing animal models(00:36:43) Sarcopenia, strength loss, and regenerative approaches to aging(00:48:10) BS201 as a long-acting pulse therapy—and how it compares to transplants

Welcome back for another dose of the Refill! Bringing you the latest insights and news in the world of mental health and pharmacy. If you want more tips and conversations about mindfulness, and mental health, checkout the Mindful PharmD Podcast on major platforms. Connect with me --> https://drmatmonharrell.bio.link/Written by Dr. Matmon Harrell ReferencesNBC News. After a suicide attempt, doctors told the Benz-Bushlings their son needed residential treatment; insurance denied his mental-health treatment anyway. (2025). NBC News. Insurance denied his mental-health treatment anyway. Retrieved from https://www.nbcnews.com/health/mental-health/insurance-denied-psychiatric-inpatient-mental-health-treatment-rcna230207MSN. FDA advisors explore a possible future with chatbot mental-health care. (2025). MSN. FDA advisors explore a possible future with chatbot mental-health care. Retrieved from https://www.msn.com/en-us/health/other/fda-advisors-explore-a-possible-future-with-chatbot-mental-health-care/ar-AA1QbcE3?ocid=BingNewsVerpSickle Cell Anemia News. Sickle Cell Anemia News. (2025). Hydroxyurea doesn't ease sleep issues in children with SCD: Study Retrieved from https://sicklecellanemianews.us5.list-manage.com/track/click?u=52c64784d386bd00ea57ee792&id=500eedf533&e=dcba61ae7aSickle Cell Anemia News. (2025). Newsletter item: First SCD patient enrolled in Phase 1b trial of oral therapy iadademstat. Retrieved from https://sicklecellanemianews.us5.list-manage.com/track/click?u=52c64784d386bd00ea57ee792&id=50c6873aa4&e=dcba61ae7aSubscribe. Share. Rate.A thousand thanks!drmatmonharrell.bio.link Hosted on Acast. See acast.com/privacy for more information.

13 Nov 2025. Dubai Exhibition Centre’s AED 10 billion expansion is powering ahead, with Phase 1 on track for completion in Q1 2026. We speak to the man leading the push, Amer Al Farsi, Vice President of Real Estate Development at DWTC, about what’s coming and why it matters for Dubai’s events economy. Plus, Dubai’s residential construction cycle is reportedly compressing, but what does that actually mean for developers, buyers and delivery timelines? Zacky Sajjad of Cavendish Maxwell breaks it down.See omnystudio.com/listener for privacy information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling updates that underscore the dynamic nature of our industry, marked by scientific breakthroughs, strategic shifts, regulatory advancements, and more.Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PF-08634404, targeting non-small cell lung cancer. This innovative approach aims to supersede Keytruda by simultaneously targeting the PD-1 and VEGF pathways, crucial in tumor growth and immune evasion. Pfizer is making substantial strides with its PD-1xVEGF bispecific antibodies by announcing seven near-term trials, including a pivotal phase 3 trial comparing this agent to Keytruda in non-small cell lung cancer. This underscores Pfizer's commitment to developing next-generation immunotherapies that could redefine cancer treatment paradigms by offering more targeted options. The implications are significant; by enhancing therapeutic efficacy through this dual-targeted strategy, Pfizer could set new standards in lung cancer treatment, potentially improving patient outcomes and redefining first-line therapies.Meanwhile, a strategic merger between Mallinckrodt and Endo has culminated in a $6.7 billion transaction, resulting in the rebranding of the combined entity as Keenova. This merger is particularly notable for its decision to spin off the Par Health generics business. Such a move indicates a focused shift towards specialty pharmaceuticals aimed at rare diseases—a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs.In financing news, Vor Bio's successful $100 million public offering highlights growing investor confidence in companies addressing autoimmune diseases. This capital will likely accelerate Vor Bio's clinical-stage programs, potentially transforming patient care in this challenging therapeutic area through new and effective treatments.On the regulatory front, Glenmark's Ryaltris has secured approval from China's National Medical Products Administration for treating moderate to severe allergic rhinitis. This approval is pivotal as Glenmark expands its footprint in respiratory therapeutics with innovative small molecule therapies designed to alleviate allergy symptoms—a sign of their strategic growth within this domain.Recent clinical trial results also offer promising news. CeleCor Therapeutics' zalunfiban has shown Phase 3 success for segment elevation myocardial infarction, while UbiVac's DPV-001 has demonstrated improved survival rates in head and neck squamous cell carcinoma. Engene's Detalimogene voraplasmid exhibited a 63% response rate in bladder cancer patients unresponsive to BCG therapy. These findings reflect ongoing advances in targeted therapies and personalized medicine approaches that continue to reshape the oncology landscape.In policy changes, the UK government has unveiled a five-year roadmap aimed at replacing animal testing with AI and 3D tissue models. This initiative marks a pivotal shift towards more ethical and technologically advanced methods in drug development, potentially accelerating discovery processes while reducing reliance on animal models—a significant move that aligns with global trends towards more humane scientific practices.Meanwhile, Richard Pazdur's appointment as director of the FDA's Center for Drug Evaluation and Research signals strategic leadership changes amidst ongoing organizational investigations. His extensive experience in oncology is expected to guide regulatory oversight during this transformative period for the agency. Dr. Richard Pazdur's appointment as director of CDER representsSupport the show

In the second part of this two-part series, Dr. Bradley Ong explains the four clinical phases of a typical migraine attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

Explore expert tips for post-operative ACL rehab, including avoiding pitfalls like lacking extension & recommended biofeedback units. Q: What is your favorite phase of post-operative care for ACL repair? A: Phase 2 is a favorite because the athlete is getting off the table, which is exciting both mentally and physically. During this phase, significant gains are made, and progress continues toward returning to running. Q: What is your biggest tip to avoid pitfalls, such as lacking extension, in post-operative care? A: Consistently checking and actively feeling for extension daily is crucial. Make it a habit and an integrated part of the treatment flow to catch any issues early. Even a little bit of load when athletes start doing more of their daily activities can affect extension, so early detection is key. Q: Is lacking extension from one treatment to the next a red flag? A: It is not necessarily a red flag, but it should definitely be noted. This observation prompts consideration of what might have changed between sessions that could have caused the lack of extension. For example, it might indicate that too much activity was introduced. Q: Should fibular head mobilizations be immediately used for lacking extension? A: No, one should not immediately jump to using fibular head mobilizations. However, they can be a successful intervention in certain cases. Q: Can this ACL rehabilitation program be used for other surgeries? A: The framework of this ACL rehabilitation program can definitely serve as a guide for other knee surgeries. However, modifications are necessary based on the specific structures that have been surgically altered. For example, a meniscus repair would require avoiding weight-bearing, unlike an isolated ACL reconstruction. Q: What biofeedback units do you recommend? A: I recommend Mtrigger. It's an app-based unit with an easy setup, and it can be used more functionally beyond just table exercises. Additionally, it is versatile and can be applied in various other post-operative cases.

In this segment, Mark is joined by David Stokes, the Director of Municipal Property at the Show Me Institute. He shares his thoughts on Governor Kehoe's plan to phase out Missouri's income tax and more.

Terry Lynch, CEO of Power Metallic Mines (TSX.V: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV), joins us for a comprehensive exploration update from their fully funded 100,000-meter drill program at the polymetallic NISK Project in Quebec.  We discuss some of the key acquisitions made earlier this year expanding the land package around the NISK Project, as well as their new Jabal Baudan claims over in Saudi Arabia.   Key Highlights from the Interview:   Exploration Strategy: A six-rig program focused on expanding the mineralized around the Lion Zone and at depth, the Tiger Zone, new polymetallic targets from surveys, and still drilling to connect the 5.5km corridor between Lion and NISK Main. High Grade Assays From Summer Drilling: 22.66 meters of 4.57% CuEq, including 6.05 meters of 9.70% CuEq in Hole 020 28.0 meters of 4.28% CuEq, including 3.4 meters of 15.45% CuEq in Hole 015 5.35 Meters of 11.97% Cu (16.35% CuEqRec) in Hole 022 Resource Growth Path: Early-stage modeling efforts are enabling analysts and investors to build their own interpretations of scale, while metallurgical studies are underway to confirm high recovery rates. Acquisition of Li-FT Power land:  Back on July 14, 2025 the Company announced that it closed a definitive agreement dated June 9, 2025 to acquire a 100% interest in 313 mineral claims totalling 167 km² from Li-FT Power Ltd. (TSXV: LIFT) (OTCQX: LIFFF). The claims adjoin the Company's 45.86km² Nisk property, where exploration is expanding the high–grade Lion Cu–PGE discovery and the Nisk Copper-Nickel-Platinum-Palladium-Gold-Cobalt deposit.   Terry explains how there are 8 very high priority drill targets that the exploration team is following up on across this newly acquired land. Phase 1 Metallurgical Testing of Lion Deposit:  On Oct. 16th, Power Metallic announced that preliminary metallurgical studies are underway being performed by SGS Canada Ltd at its laboratories based in Quebec City, QC, and Lakefield, ON. Work to date has shown that the copper mineralization is contained within coarse grained chalcopyrite and cubanite, both which should respond well to conventional sulphide concentration methods. Overall, the character of the mineralization suggests good recoveries of copper sulphides, and these initial metallurgical tests will determine the recovery potential of the PGEs, Au, Ag, and Ni., which are expected to report within a conventional sulphide concentrate. Awarded Jabal Baudan Exploration License in Saudi Arabia: Power Metallic announced on June 16th that it was awarded the exploration license for the Jabal Baudan project in Saudi Arabia's Jabal Sayid Mineralized Belt. This historic milestone positions Power Metallic as one of the few foreign companies with mining concessions in the Kingdom of Saudi Arabia, having secured a successful bid in this prestigious licensing process. Key Strategic Stakeholders:   Terry highlights that there are high profile backers of the company like Robert Friedland, Rob McEwen, The Stern Family, Palos Capital, and also Terry's family that are keeping a large percentage of the shares in strong hands interested in seeing the longer-term expansion of the mineralization for the company.  * In full disclosure, Shad is a shareholder of Power Metallic Mines at the time of this recording and may choose to buy or sell shares at any time.    Click here to follow the latest news from Power Metallic Mines   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

In part one of this two-part series, Dr. Bradley Ong discusses the prodrome phase of migraine and how it represents the earliest stage of the attack.  Show citation:  Lipton RB, Stokes J, Evans CJ, et al. Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing. Headache. 2025;65(8):1355-1368. doi:10.1111/head.15024 

Puny Podians Assemble! Ryan and David are back in the Super Secret Spoiler Show vault, this time diving into Iron Man 3—the movie that kicked off Phase 2 and split fans faster than Tony's suits falling apart mid-flight. They're breaking down Shane Black's snarky, Christmas-set spin on the Iron Avenger: the Mandarin twist, PTSD Tony, an army of exploding Extremis soldiers, and a whole lot of suits. From Iron Man 3's divisive legacy to its surprising emotional depth, this episode covers what worked, what whiffed, and why it still sparks debate across MCU fandom. Plus, the usual SSSS chaos—Skrull of the Movie, product placement awards (looking at you, Audi), facial hair rankings, and the eternal question: which role would Nicolas Cage absolutely overact to perfection? Whether you think Iron Man 3 is underrated brilliance or Tony's weakest link, this spoiler-filled deep dive is loaded with armor, attitude, and absurdity. Hit play and let's power up! Learn more about your ad choices. Visit megaphone.fm/adchoices

Bei Gesprächen über die Gaza-Friedenspläne in Jerusalem haben US-Sonderberater Jared Kushner und Israels Regierungschef Benjamin Netanjahu sowohl über die derzeitige erste Phase, als auch über die nächste Phase beraten.

Kingfisher Metals reported additional drill and soil results from its 2025 program at the HWY 37 Project in British Columbia's Golden Triangle. Nevada King Gold Corp. reported final results from ten remaining holes of its Phase III drill program at the Silver Park East (SPE) target. Collective Mining announced that drilling is now fully underway at the high-grade, tungsten-rich zones of its **Apollo system**. Great Pacific Gold announced Phase 1 diamond drill results from the Sinivit target at its flagship Wild Dog Project in Papua New Guinea. First Mining Gold announced additional 2025 exploration results from the Miroir target at its Duparquet Gold Project in Quebec's Abitibi region. Foran Mining announced H2 2025 exploration results from the Tesla Zone at its McIlvenna Bay Project in Saskatchewan.This episode of Mining Stock Daily is brought to you by… Integra ResourcesIntegra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.comThe Mining Stock Daily morning briefing is produced by Clear Commodity Network. It is distributed throughout the world through your podcast network of choice, and by our friends at the Junior Mining Network. The information presented should not be considered investment advice. Mining stock daily and its affiliates are not responsible for any loss arising from any investment decision in connection with the material presented herein. Please do your own research or speak with a licensed financial representative before making any investment decisions.

Have you ever been in a relationship where your partner starts to feel less romantic, more platonic, or even like your flatmate? You might have experienced roommate syndrome. In this episode with special cohost Jordan Barr, we work out the telltale the signs of a roomie phase, unpack the reasons why it happens and debate whether we should be reframing our expectations of long term relationships.SHOW NOTES:How to get the spark back in your relationship:  https://www.abc.net.au/triplej/programs/the-hook-up/how-to-get-intimacy-back-in-your-relationship-emotional-spark/104535358Has social media cooked our expectations of dating? https://www.youtube.com/watch?v=rilv_GuNQD4Should your partner be your best friend?https://www.abc.net.au/triplej/programs/the-hook-up/should-your-partner-be-best-friend-soulmate-relationship/104132010DM us your thoughts, questions, topics, or to just vent at @triplejthehookup on IG or email us: thehookup@abc.net.auThe Hook Up is an ABC podcast, produced by triple j. It is recorded on the lands of the Wurundjeri people of the Kulin nation. We pay our respects to elders past and present. We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the land where we live, work, and learn.

Have you ever been in a relationship where your partner starts to feel less romantic, more platonic, or even like your flatmate? You might have experienced roommate syndrome. In this episode with special cohost Jordan Barr, we work out the telltale the signs of a roomie phase, unpack the reasons why it happens and debate whether we should be reframing our expectations of long term relationships.

This final lesson covers Phase 3—"the talk"—the structured, honest conversation where you clearly state your non-monogamous terms after the 3–5 month implicit phase. You'll learn the right timing, setting, and messaging (the "Disney sandwich") to maximize acceptance, manage reactions without drama, and negotiate clear boundaries for a sustainable long-term arrangement.

Diese Meditation hilft dir, zur Ruhe zu kommen und wieder klarer zu spüren, was dir wichtig ist. Zunächst wirst du sanft angeleitet, bei dir selbst anzukommen – danach folgt eine etwa zehnminütige Phase in Stille, in der du einfach nur da sein darfst. Ideal, wenn du dich dir einen Moment für Klarheit, Ruhe und Selbstverbindung wünschst.

Listener feedback on non-culprit PCI in STEMI, a major cardiac result in patients on hemodialysis, news on GLP-1 agonists, a dubious stroke trial, and an AHA preview are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Meta-analysis of MI as a surrogate https://pubmed.ncbi.nlm.nih.gov/34694318/ Compare Acute Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1701067 DANAMI-3–PRIMULTI 10.1016/S0140-6736(15)60648-1 External Link CULPRIT-SHOCK https://www.nejm.org/doi/full/10.1056/NEJMoa1710261   II  Huge Cardiac News for Patients with ESRD PISCES article EMBARGOED Till 1130 AM EST PISCES Trial www.nejm.org/doi/full/10.1056/NEJMoa2513032 REDUCE-IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1812792 STRENGTH Trial https://jamanetwork.com/journals/jama/fullarticle/2773120 FISH trial https://jamanetwork.com/journals/jama/fullarticle/1150094 III Obesity Agents White House announces deal with Lilly and Novo on GLP-1 drugs https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-shares-rise-trump-obesity-drug-deal-nears-2025-11-06/ Amylin Agonists Amylin Analog Eloralintide Reduces Weight in Phase 2 Trial https://www.medscape.com/viewarticle/amylin-analog-eloralintide-reduces-weight-phase-2-trial-2025a1000uqf Eloralintide Phase 2 Study https://doi.org/10.1016/S0140-6736(25)02155-5 GLP-1 Comparisons SURMOUNT-5 Trial https://www.nejm.org/doi/10.1056/NEJMoa2416394 Tirzepatide vs Semaglutide in 10-year CVD Risk Reduction https://doi.org/10.1093/ehjopen/oeaf117 IV A Problematic Trial in Stroke Care LAMP trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2840370 V AHA Preview AHA 2025: Mandrola's Four Trials to Look For https://www.medscape.com/viewarticle/aha-2025-mandrolas-four-trials-look-2025a1000u80 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Show Features: Internet Is Undefeated, Blooper Reel and VoicemailsSocials: @DaveandMahoney Voice Mail: 833-Yo-Dummy https://www.twitch.tv/daveandmahoney Additional Content: daveandmahoney.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.